This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients with multiple myeloma
Number of approved sites
Paper on the second revision of the International Staging System (R2-ISS) accepted for publication!Read more
The MRDR was recently represented at the 4th National Myeloma Workshop.Read more
Thank you to all attendees for contributing to a successful MRDR Interest Group breakfast at Blood 2022!Read more
Paper on on early mortality in multiple myeloma accepted for publication!Read more